A group of patients recently started various new antidiabetic therapies and subsequently developed medication-induced complications. Based on the distinct pharmacological profiles of these agents, match each antidiabetic medication to the clinical scenario that best describes its most characteristic adverse effect.
- CanagliflozinA patient presents with recurrent perineal pruritus and a thick, white vaginal discharge.
- PioglitazoneA patient with a history of ischemic cardiomyopathy develops progressive exertional dyspnea and bilateral pedal edema.
- LiraglutideA patient presents with severe epigastric pain radiating to the back, nausea, and an elevated serum lipase.
- GlipizideAn elderly patient is brought in with diaphoresis, confusion, and a capillary blood glucose of 42 mg/dL.
- MetforminA patient develops progressive symmetrical numbness in the lower extremities and macrocytic anemia over several years.
Answer
Canagliflozin maps to perineal pruritus (candidiasis). Pioglitazone maps to dyspnea/edema (heart failure exacerbation). Liraglutide maps to epigastric pain/elevated lipase (pancreatitis). Glipizide maps to hypoglycemia. Metformin maps to lower extremity numbness/macrocytic anemia (B12 deficiency).
Each antidiabetic medication has a distinct side effect profile based on its mechanism of action. SGLT2 inhibitors (canagliflozin) increase urinary glucose, leading to genitourinary fungal infections. Thiazolidinediones (pioglitazone) promote fluid retention by acting on the collecting tubule, worsening heart failure. GLP-1 agonists (liraglutide) stimulate the pancreas but carry a known risk of pancreatitis. Sulfonylureas (glipizide) directly stimulate beta-cell insulin release independent of serum glucose, precipitating hypoglycemia. Metformin impairs intestinal absorption of vitamin B12, leading to megaloblastic anemia and subacute combined degeneration if left uncorrected.
Step-by-Step Solution
Key Concept
Adverse effect profiles of distinct antidiabetic medication classes.